Drug Scheduling Actions

Final Rule: Placement of Serdexmethylphenidate in Schedule IV (PDF) (June 24, 2022)

Final Rule: Placement of Methoxetamine (MXE) in Schedule I (PDF) (June 6, 2022)

Interim Final Rule: Placement of Ganaxolone in Schedule V (PDF) (June 1, 2022)

Final Rule: Placement of N-Ethylhexedrone, alpha-Pyrrolidinohexanophenone, 4-Methyl-alpha-ethylaminopentiophenone, 4′-Methyl-alpha-pyrrolidinohexiophenone, alpha-Pyrrolidinoheptaphenone, and 4′-Chloro-alpha-pyrrolidinovalerophenone in Schedule I (PDF) (June 1, 2022)

Temporary Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I (PDF) (April 12, 2022)

Final Rule: Requiring Online Submission of Applications for and Renewals of DEA Registration (PDF) (April 11, 2022)

Interim Final Rule: Placement of Daridorexant in Schedule IV (PDF) (April 7, 2022)

Final Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 in Schedule I (PDF) (April 7, 2022)

Exempt Chemical Preparations under the Controlled Substances Act

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 19, 2022)

Exempt Chemical Preparations Under the Controlled Substances Act; Correction (PDF) (February 3, 2022)

Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (January 21, 2022)

Proposed Rules

Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I (PDF) (July 6, 2022)

Proposed Rule: Exempted Prescription Products (PDF) (April 12, 2022)

Proposed Rule: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I (PDF) (April 11, 2022)

Proposed Rule: Placement of 4-hydroxy-N,N-diisopropyltryptamine, 5-methoxy-alpha-methyltryptamine, 5-methoxy-N-methyl-N-isopropyltryptamine, 5-methoxy-N,N-diethyltryptamine, and N,N-diisopropyltryptamine in Schedule I (PDF) (January 14, 2022)

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).